Program
molnupiravir
Also written as “Molnupiravir”, “EIDD-2801” and “MK-4482”.
Its studies are mostly in COVID-19 · Renal Insufficiency · Coronavirus Infections, led by 4 companies.
Drug pageMolnupiravir: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 91 open or running | phase 3since Sep 30, 2020 | Sep 30, 2020 | Jan 26, 2031phase 3 · NCT06667700 |
| Ridgeback Biotherapeutics, LP | 30 open or running | phase 2since May 26, 2020 | Apr 29, 2020 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Dec 7, 2022 | Dec 7, 2022 | none ahead |
| Valenta Pharm JSCits history only | 10 open or running | no phasesince Jun 6, 2022 | Jun 6, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ridgeback Biotherapeutics, LP only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 29, 2020First study: phase 1 study in Coronavirus InfectionsFirst studyNCT04392219 · 130 enrolled · United Kingdom
- May 26, 20202 phase 2 studiesNCT04405739, NCT04405570
- Dec 19, 2020Named molnupiravirINNProposed as its International Nonproprietary Name in WHO's List 124 · before, EIDD-2801, MK-4482
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RNA disrupting agent”ChEMBL 37, by rule
Studies
All 3 Ridgeback Biotherapeutics, LP leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04405739SARS-CoV 2 · United States | 2 | Completed | Feb 21, 2022 | 71 |
| NCT04405570COVID-19 · United States | 2 | Completed | Feb 21, 2021 | 204 |
| NCT04392219Coronavirus Infections · United Kingdom | 1 | Completed | Aug 11, 2020 | 130 |
How it is read
Names in the registry
- “Molnupiravir”, 9 entries
- “EIDD-2801”, 2 entries
- “MK-4482”, 1 entry
- “GP30341 capsules 200 mg”, 1 entry
- “Molnupiravir 200 mg”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 8 studies
- Renal Insufficiency, 1 study
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.